The randomized controlled trials (RCTs) that investigated the effectiveness of UDCA in NAFLD were selected and examined by Stata (version 12.0). Results: The forest plot displayed that UDCA treatment can significantly decrease the ALT (alanine aminotransferase) levels (p=0.007).

Ursodeoxycholic acid was beneficial in patients diagnosed with NAFLD as it significantly reduced aspartate transaminase, ALT and GGT levels. However, more randomized controlled trials are required to be conducted in the future to increase the certainty of the evident findings.

Ursodeoxycholic acid (UDCA) is a non-toxic, hydrophilic bile acid indicated for treatment of gallstones and primary biliary cirrhosis (PBC). 1 Endogenous bile acids are hepatically synthesized and regulate cholesterol homeostasis and solubilization of dietary lipids.

2020年8月27日 · Our finding revealed that UDCA exerted obviously favorable influence on hepatic steatosis in NAFLD rats by activating AMP-activated protein kinase (AMPK). Mechanistic studies indicated UDCA inhibited apoptosis and improved autophagy by influencing Bcl-2/Beclin-1 and Bcl-2/Bax complex interaction.

Here we aimed to explore the molecular and biochemical mechanisms of ursodeoxycholic acid (UDCA) in modulating the cross-talk between liver and visceral white adipose tissue (vWAT) regarding BA and cholesterol metabolism and fatty acid/lipid partitioning in …

2021年3月14日 · Ursodeoxycholic acid (UDCA), which is one of the first-line therapeutic agents for treatment of NAFLD, is reported to have a beneficial effect on dyslipidemia and ASCVD risk because of antioxidant properties.

调查 UDCA 在 NAFLD 中的有效性的随机对照试验 (RCT) 由 Stata 选择和检查（ 12.0 版）。结果 森林图显示 UDCA 治疗可以显着降低 ALT（丙氨酸转氨酶）水平 (p=0.007)。此外，它在亚组分析中的重要作用（欧洲人群 p=0.003，50 岁以上人群 p=0.001 和更长持续时间 p=0.008）。

The effects of UDCA in NAFLD can be explained by the numerous antioxidant mechanisms on dyslipidemia and the reduction of the risk of cardiovascular disease by the protective effects on iron-dependent oxidative reactions and hydroxide radicals.

Background and Objectives: The role of ursodeoxycholic acid (UDCA) in Nonalcoholic fatty liver disease (NAFLD) is not well-defined. In this meta-analysis, we analyzed the efficacy of UDCA for the treatment of

2024年5月1日 · Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid commonly used for treating cholestatic liver disease. However, its efficacy on non-alcoholic steatohepatitis (NASH) was controversial. This study aimed to investigate the impact of a high dosage of UDCA on a mouse model of NASH.